Amryt Pharma (NASDAQ:AMYT – Get Rating) will issue its quarterly earnings data before the market opens on Thursday, August 4th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Amryt Pharma (NASDAQ:AMYT – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $59.13 million for the quarter, compared to the consensus estimate of $57.48 million. Amryt Pharma had a negative net margin of 6.91% and a positive return on equity of 3.65%. During the same period in the prior year, the firm earned ($0.09) earnings per share. On average, analysts expect Amryt Pharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Amryt Pharma Price Performance
NASDAQ AMYT opened at $7.47 on Thursday. The company has a market cap of $477.80 million, a PE ratio of -82.99 and a beta of 0.30. Amryt Pharma has a 52 week low of $5.61 and a 52 week high of $12.45. The company has a quick ratio of 1.04, a current ratio of 1.88 and a debt-to-equity ratio of 0.59. The firm’s 50-day simple moving average is $7.42 and its two-hundred day simple moving average is $8.18.
Institutional Investors Weigh In On Amryt Pharma
Analysts Set New Price Targets
Separately, SVB Leerink reaffirmed an “outperform” rating and set a $19.00 price objective (up from $18.00) on shares of Amryt Pharma in a report on Friday, June 24th.
Amryt Pharma Company Profile
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia.
- Get a free copy of the StockNews.com research report on Amryt Pharma (AMYT)
- The MarketBeat Podcast: Portfolio Management in Market Downturns
- Can These Two Airline Stocks Overcome Gravity And Fly Higher?
- Shopify Stock Rallies Despite Quarterly Loss
- Two Automation Stocks The Institutions Are Buying
- Can Owens-Corning Insulate Your Portfolio?
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.